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Purpose: Accelerated partial breast irradiation (APBI) with balloon and strut adjusted volume implants (SAVI) show
promising results with excellent tumor control and minimal toxicity. Knowing the factors that contribute to a high
skin dose, rib dose, and D95 coverage may reduce toxicity, improve tumor control, and help properly predict patient
outcomes following APBI.
Methods and materials: A retrospective analysis of 594 patients treated with brachytherapy based APBI at a single
institution from May 2008 to September 2014 was grouped by applicator subtype. Patients were treated to a total
of 34 Gy (3.4 Gy x 10 fractions over 5 days delivered BID) targeting a planning target volume (PTV) 1.0 cm beyond
the lumpectomy cavity using a high dose rate source.
Results: SAVI devices had the lowest statistically significant values of DmaxSkin (81.00 ± 29.83), highest values of D90
(101.50 ± 3.66), and D95 (96.09 ± 4.55). SAVI-mini devices had the lowest statistically significant values of DmaxRib
(77.66 ± 32.92) and smallest V150 (18.01 ± 3.39). Multi-lumen balloons were able to obtain the smallest V200 (5.89 ±
2.21). Strut-based applicators were more likely to achieve a DmaxSkin and a DmaxRib less than or equal to 100 %. The
effect of PTV on V150 showed a strong positive relationship (p < .001). PTV and DmaxSkin showed a weak negative
relationship in multi-lumen applicators (p = .016) and SAVI-mini devices (p < .001). PTV and DmaxRib showed a weak
negative relationship in multi-lumen applicators (p = .009), SAVI devices (p < .001), and SAVI-mini devices (p < .001).
Conclusion: PTV volume is strongly correlated with V150 in all devices and V200 in strut based devices. Larger PTV
volumes result in greater V150 and V200, which could help predict potential risks for hotspots and resulting toxicities
in these devices. PTV volume is also weakly negatively correlated with max skin dose and max rib dose, meaning
that as the PTV volumes increase one can expect slightly smaller max skin and rib doses. Strut based applicators are
significantly more effective in keeping skin and rib dose constraints under 125 and 100 % when compared to any
balloon based applicator.
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Accelerated partial breast irradiation (APBI) has gained
popularity as an alternative option to deliver adjuvant
radiation therapy (RT) after lumpectomy in select patient
populations with early stage breast cancer [1]. Several dif-
ferent forms of RT can be used to deliver APBI, including
interstitial multicatheter brachytherapy, balloon catheter* Correspondence: rhong@virginiahospitalcenter.com
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creativecommons.org/publicdomain/zero/1.0/brachytherapy, intraoperative radiation therapy, and con-
formal external beam radiation therapy [2]. Initial data has
been reported using interstitial multicatheter brachyther-
apy, a technique that uses image guidance for the inser-
tion of multiple afterloading catheters around the
lumpectomy cavity, resulting in excellent target coverage
and conformality [3–6]. Despite 10-year interstitial multi-
catheter brachytherapy results showing a local control
rate ≥ 95 %, and excellent cosmetic outcomes in 90 % of
patients, physician acceptance has been slow [7–10, 6].cle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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technical skill required for a successful interstitial implant
[3, 11].
The MammoSite Single-Lumen (MS-SL) applicator
(Hologic Inc, Bedford, MA) was introduced to simplify
application and make results reproducible. The Mam-
moSite catheter is composed of a 15 cm double-lumen
catheter, that is 6 mm in diameter, and connected to a
silicone balloon. The balloon is inflated to a size that
completely fills the lumpectomy cavity and the prescrip-
tion radiation dose is inserted through the catheter into
the balloon [2]. A minimum balloon-to-skin distance of
5 mm is required with a threshold of at least 7 mm
strongly recommended, as longer skin distance is associ-
ated with improved cosmesis [12–14]. MammoSite has
been shown to be effective with low local recurrence
rates and toxicity rates in both single institutional expe-
riences and large multi-institutional experiences, like the
American Society of Breast Surgeons MammoSite regis-
try trial [15, 16]. Patients with small breasts or upper-
inner quadrant tumors are not eligible for MS-SL due to
the balloon surface being too close to the skin. Further-
more, since the device contains a single central source
channel, geometry is fixed and dose optimization is lim-
ited [17, 18].
In order to eliminate dosimetric limitations seen in
single lumen devices, Hologic introduced a Mammo-
Site Multi-lumen (MS-ML) device and the Contura
Multi-Lumen Balloon (Bard Biopsy Systems, Tempe,
AZ) was developed. The MS-ML device has fewer
outer lumens (3 vs. 4) with a shorter offset (3 mm vs.
5 mm) from the central lumen when compared with
the Contura device, but the two devices have been
shown to produce a clinically comparable plan [19].
The outer lumens provide additional source positions
and better dose flexibility when compared with a
single-catheter approach. Multi-lumen catheters have
also shown improvements in rib doses, skin doses,
and PTV-EVAL coverage, when compared to single-
lumen devices [20].
While multicatheter brachytherapy provides superior
versatility and dosimetric conformity, they also require
multiple skin incisions for placement. Hybrid brachyther-
apy devices were developed to provide dosimetric advan-
tages while maintaining the simplicity and aesthetics of
single-catheter breast brachytherapy devices [2]. The Strut
Adjusted Volume Implant (SAVI) device (Cianna Med-
ical, AlisoViejo, CA) is placed into a lumpectomy cavity
through a single incision. The SAVI applicator itself has
a central catheter as well as 6, 8, or 10 peripheral cathe-
ters that are expanded outwards to the periphery of the
lumpectomy cavity after insertion [21]. The central and
peripheral catheters contain a large number of potential
dwell positions for the radiation source and are indirect contact with the lumpectomy cavity edge, provid-
ing flexibility in dose distribution [22].
APBI using balloon and strut-based applicators show
promising results with excellent tumor control and min-
imal toxicity [23]. A higher dose to 95 % of the planning
target volume (D95) is important in achieving tumor
control [24]. Achieving better cosmetic outcomes and
reducing toxicity requires reduction in normal tissue ex-
posure. Telangiectasia development has been shown to
be a function of skin dose. The Virginia Commonwealth
University experience, Contura phase IV registry trial,
and recommendations in the ongoing NSABP-B39 proto-
col proposed skin consraints of ≤120, ≤125, and ≤145 %
[25, 3]. However, recently published data suggest that skin
doses ≥ 100 % may represent a stronger predictor of late
telangiectasia [23].
Knowing the factors that contribute to a high skin
dose, rib dose, V150, V200, and D95 coverage may re-
duce toxicity, improve tumor control, and help properly
predict patient outcomes following APBI. We present here
our single-institution dosimetric performance with Mam-
mosite, Contura, and SAVI APBI. We further characterize
dosimetric correlates to reduce toxicity and maximize cos-
metic preservation.
Methods and materials
A total of 594 patients, with localized breast cancer
treated with brachytherapy based APBI at a single insti-
tution from May 2008 to September 2014, were retro-
spectively reviewed as part of a prospectively maintained
institutional database. Due to the retrospective nature of
this study, it was granted an exemption in writing by the
Virginia Hospital Center IRB. Of the 594 patients, there
were 496 strut based implants, including SAVI 6-1 mini,
6-1, 8-1, and 10-1 devices, but because of SAVI 6-1
mini’s unique size it was separated into its own group.
Multi-catheter balloon implants consisted of 54 Contura
devices and 10 MammoSite mulit-lumen devices. Be-
cause the two devices have been shown to produce simi-
lar plans, they were combined into one multi-lumen
balloon subgroup. Categories used for statistical analysis
included 243 SAVI devices, 253 SAVI 6-1 mini devices,
64 multi-lumen balloons, and 34 Mammosite single-
lumen balloons.
Generally inclusion criteria for APBI were in accord-
ance with the American Society of Breast Surgeons
(ASBS) and the American Society for Radiation Oncol-
ogy (ASTRO): invasive carcinoma or ductal carcinoma
in situ, tumor <3 cm, negative microscopic surgical mar-
gins, negative lymph nodes, and age 45 or older.
Patients were treated to a total of 34 Gy (3.4 Gy x 10
fractions over 5 days delivered BID) targeting a PTV
1 cm beyond the lumpectomy cavity using a high dose rate
source. Minimum treatment planning goals for the
Table 1 Baseline patient treatment characteristics
Patients (N = 594)
Age (y/o) Median 63 (37–92)
>60, n (%) 342 (57.6 %)
50–60, n (%) 173 (29.1 %)
>40–50, n (%) 78 (13.1 %)
<40, n (%) 1 (0.2 %)
Tumor location, n (%) Left breast 297 (50.0 %)
Right breast 297 (50.0 %)
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October 2011, PTV coverage goals were adjusted to
D95 > 95 %. Size of the planning target volume, absolute
volume of the tissue receiving 150 % of the prescription
dose (V150), and volume of tissue receiving 200 % (V200),
were evaluated. 3D treatment planning system was used
to obtain the maximal point doses delivered to the skin
and chest wall.
Statistical analysis was performed with SPSS v22.0
(SPSS Inc, Chicago, IL). Statistical significance was defined
as p < .05. Multiple analysis-of-variance (MANOVA) was
performed to search for possible differences between cath-
eter subtypes. Dosimetric parameters were then compared
across catheter subtype using Student’s t-test (α < 0.05).
Multiple logistic regression with backward elimination was
used in the multivariate analysis to search for possible pre-
dicting factors for maximum skin dose, maximum rib dose,
and D95. Pearson’s correlation coefficient was used to see
PTV’s effect on D90, D95, V150, V200, DmaxSkin, and DmaxRib.
Specifically, the basis of this analysis was to determine if lar-
ger PTV volumes would cause an increase in maximum
doses and potential toxicities. A strong relationship was
defined as an r-value greater than 0.5 or less than−0.5 with
p < .05. A weak relationship was defined as an r-value
between 0.25 and 0.5 or−0.25 and−0.5 with p < .05.Table 2 Dose distribution parameters (mean values and standard de
Single-lumen (n = 34) Multi-lumen (n = 64)
D90 (%) 97.33 ± 4.75 94.16 ± 6.54
D95 (%) 95.74 ± 7.47 90.06 ± 7.90
DmaxSkin 108.56 ± 30.44 114.09 ± 34.10
DmaxRib 114 ± 43.82 105.03 ± 47.80
V150 (cm
3) 29.86 ± 5.44 23.44 ± 5.98
V200 (cm
3) 6.34 ± 2.17 5.89 ± 2.21
PTV (cm3) 94.62 ± 14.72 80.88 ± 19.55Results
The baseline characteristics for included patients (n = 594)
are shown in Table 1. The mean values with the standard
deviations of achieved dosimetric characteristics are
shown in Table 2 and Fig. 1. Student’s t-test was used
to compare the dosimetric characteristics across each
type of APBI device (Tables 3, 4 and 5).
DmaxSkin
The lowest values of DmaxSkin were obtained in the
SAVI devices (81.00 ± 29.83). This mean difference
was significantly less than single-lumen balloon appli-
cators (−27.56, p < .001), multi-lumen balloon applica-
tors (−33.09, p < .001), and SAVI-mini devices (−15.20,
p < .001) (Table 3). Strut-based applicators (SAVI:
0.8 %, SAVI-mini: 4.0 %) were much less likely to re-
ceive a DmaxSkin greater than or equal to 125 %,
when compared to single-lumen (32.4 %) and multi-
lumen balloon applicators (31.3 %) (Fig. 2). Strut-
based applicators were also more likely to achieve a
DmaxSkin less than or equal to 100 % with SAVI de-
vices achieving this 65.8 % of the time.
Dmax Rib
The lowest values of Dmax Rib were seen in the
SAVI-mini devices (77.66 ± 32.92). The mean differ-
ence in SAVI-mini devices was statistically significant
when compared to single-lumen balloon applicators
(−36.34, p < .001) and multi-lumen balloon applica-
tors (−27.37, p < .001). There was no statistically sig-
nificant difference in DmaxRib when comparing
SAVI-mini devices with SAVI devices. Strut-based
devices were able to achieve a DmaxRib less than or
equal to 100 % in 70 % of patients treated, which
was more frequent than the single-lumen balloon ap-
plicators (35.3 %) and multi-lumen balloon applica-
tors (43.8 %) (Fig. 3).
D90 and D95
SAVI devices had the highest values of D90 (101.50 ±
3.66) and D95 (96.09 ± 4.55). When compared to multi-
lumen balloon applicators, strut-based devices had aviation) across catheter subtype
SAVI (n = 243) SAVI-mini (n = 253) All Devices (n = 594)
101.50 ± 3.66 100.45 ± 5.48 100.02 ± 5.40
96.09 ± 4.55 94.12 ± 6.61 94.58 ± 6.33
81.00 ± 29.83 96.20 ± 27.17 92.62 ± 31.26
78.06 ± 32.87 77.66 ± 32.92 82.85 ± 37.16
24.32 ± 4.69 18.01 ± 3.39 21.85 ± 5.66
10.74 ± 2.88 9.28 ± 1.87 9.34 ± 2.87
60.15 ± 12.89 40.36 ± 7.13 55.93 ± 20.14
Fig. 1 Mean dosimetric values +/−one standard deviation across APBI device (a) D90 (b) D95 (c) V150 (d) V200 (e) DmaxRib (f) DmaxSkin (g) PTV
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p < .001) and D95 mean difference (6.02, p < .001)
(Table 4). However, the difference was not statistically
significant different when compared to single-lumen
devices.V150 and V200
SAVI-mini devices obtained the smallest V150 (18.01 ±
3.39) and this mean difference was significantly smaller
than single-lumen (−11.85, p < .001), multi-lumen (−5.44,
p < .001), and SAVI devices (−6.31, p < .001) (Table 5).
Table 3 Comparison of skin and rib doses between APBI devices
Dependent
Variable
(I) Applicator (J) Applicator Mean Difference (I–J) Std. Error p
DmaxSkin Single-lumen Multi-lumen −5.5242 6.20960 .374
Savi 27.5618 5.35769 < .001
Savi-mini 12.3611 5.34468 .021
Multi-lumen Single-lumen 5.5242 6.20960 .374
Savi 33.0860 4.11108 < .001
Savi-mini 17.8853 4.09411 < .001
Savi Single-lumen −27.5618 5.35769 < .001
Multi-lumen −33.0860 4.11108 < .001
Savi-mini −15.2007 2.62820 < .001
Savi-mini Single-lumen −12.3611 5.34468 .021
Multi-lumen −17.8853 4.09411 < .001
Savi 15.2007 2.62820 < .001
DmaxRib Single-lumen Multi-lumen 8.9750 7.52486 .233
Savi 35.9376 6.49250 < .001
Savi-mini 36.3416 6.47673 < .001
Multi-lumen Single-lumen −8.9750 7.52486 .233
Savi 26.9626 4.98185 < .001
Savi-mini 27.3666 4.96129 < .001
Savi Single-lumen −35.9376 6.49250 < .001
Multi-lumen −26.9626 4.98185 < .001
Savi-mini .4040 3.18487 .899
Savi-mini Single-lumen −36.3416 6.47673 < .001
Multi-lumen −27.3666 4.96129 < .001
Savi −.4040 3.18487 .899
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obtain the smallest volume (5.89 ± 2.21). This volume was
significantly smaller than SAVI (−4.85, p < .001) and
SAVI-mini devices (−3.40, p < .001), but when comparing
V200 obtained in multi-lumen and single-lumen applica-
tors there was no significant difference.
PTV
PTV was statistically significantly smaller when SAVI
and SAVI-mini devices were used as opposed to single-
lumen and multi-lumen balloon applicators (Tables 2
and 5). The effect of PTV on dosimetric characteristics
was observed using Pearson’s correlation coefficient in
order to determine if larger PTV volumes resulted in
greater maximum doses. When looking at all the devices
together (n = 594), V150 was the only dosimetric con-
straint to show a strong positive relationship with PTV
(r= .783, p < .001) (Table 6). This strong positive relationship
between PTV and V150 was also observed when devices
were stratified between SAVI (r = .808, p < .001), SAVI-
mini devices (r = .826, p < .001), multi-lumen applicators(r = .547, p < .001), and single-lumen applicators (r = .513,
p < .001). PTV and V200 showed a strong positive relation-
ship in SAVI-mini devices (r = .586, p < .001) and a weak
positive relationship in SAVI devices (r = .266, p < .001).
PTV and DmaxSkin showed a weak negative relation-
ship in multi-lumen applicators (r= -.301, p = .016) and
SAVI-mini devices (r=−.350, p < .001). PTV and DmaxRib
showed a weak negative relationship in multi-lumen applica-
tors (r=−.325, p= .009), SAVI devices (r = .407, p < .001),
and SAVI-mini devices (r =−.297, p < .001). PTV had a
weak positive relationship with D90 in multi-lumen bal-
loon applicators (r = .388, p = .002) and SAVI-mini devices
(r = .335, p < .001). PTV also had a weak positive relation-
ship with D95 in multi-lumen balloon applicators (r = .382,
p = .002) and SAVI-mini devices (r = .405, p < .001).
Of the 594 patients treated, 139 of the patients were
followed for three years after treatment. There were 3
local failures (2.2 %) after three years resulting in a local
control rate of 97.8 %. There were a total of 2 contralat-
eral failures (1.4 %). Two and three year disease free
survival rate were 98.8 and 96.3 % respectively.
Table 5 Comparison of PTV, V150, and V200 between APBI
devices
(I) Applicator (J) Applicator Mean
Difference (I–J)
Std. Error p
PTV Single-lumen Multi-lumen 13.7353 2.53559 < .001
Savi 34.4664 2.18772 < .001
Savi-mini 54.2576 2.18241 < .001
Multi-lumen 13.7353 2.53559 < .001
Multi-lumen Single-lumen −13.7353 2.53559 < .001
Savi 20.7310 1.67869 < .001
Savi-mini 40.5222 1.67176 < .001
Savi Single-lumen −34.4664 2.18772 < .001
Multi-lumen −20.7310 1.67869 < .001
Savi-mini 19.7912 1.07318 < .001
Savi-mini Single-lumen −54.2576 2.18241 < .001
Multi-lumen −40.5222 1.67176 < .001
Savi −19.7912 1.07318 < .001
V150 Single-lumen Multi-lumen 6.4121 .93452 < .001
Savi 5.5340 .80631 < .001
Savi-mini 11.8479 .80435 < .001
Multi-lumen Single-lumen −6.4121 .93452 < .001
Savi −.8782 .61870 .156
Savi-mini 5.4357 .61615 < .001
Savi Single-lumen −5.5340 .80631 < .001
Multi-lumen .8782 .61870 .156
Savi-mini 6.3139 .39553 < .001
Savi-mini Single-lumen −11.8479 .80435 < .001
Multi-lumen −5.4357 .61615 < .001
Savi −6.3139 .39553 < .001
V200 Single-lumen Multi-lumen .4523 .50586 .372
Savi −4.4003 .43646 < .001
Savi-mini −2.9443 .43540 < .001
Multi-lumen Single-lumen −.4523 .50586 .372
Savi −4.8526 .33490 < .001
Savi-mini −3.3966 .33352 < .001
Savi Single-lumen 4.4003 .43646 < .001
Multi-lumen 4.8526 .33490 < .001
Savi-mini 1.4560 .21410 < .001
Savi-mini Single-lumen 2.9443 .43540 < .001
Multi-lumen 3.3966 .33352 < .001
Savi −1.4560 .21410 < .001
Table 4 Comparison of D90 and D95 between APBI devices
(I) Applicator (J) Applicator Mean Difference
(I–J)
Std. Error p
D90 Single-lumen Multi-lumen 3.1699 1.04264 .002
Savi −4.1677 .89960 < .001
Savi-mini −3.1167 .89741 .001
Multi-lumen Single-lumen −3.1699 1.04264 .002
Savi −7.3376 .69028 < .001
Savi-mini −6.2866 .68743 < .001
Savi Single-lumen 4.1677 .89960 < .001
Multi-lumen 7.3376 .69028 < .001
Savi-mini 1.0510 .44129 .018
Savi-mini Single-lumen 3.1167 .89741 .001
Multi-lumen 6.2866 .68743 < .001
Savi −1.0510 .44129 .018
D95 Single-lumen Multi-lumen 5.6730 1.29051 < .001
Savi −.3506 1.11346 .753
Savi-mini 1.6171 1.11076 .146
Multi-lumen Single-lumen −5.6730 1.29051 < .001
Savi −6.0236 .85439 < .001
Savi-mini −4.0559 .85086 < .001
Savi Single-lumen .3506 1.11346 .753
Multi-lumen 6.0236 .85439 < .001
Savi-mini 1.9677 .54620 < .001
Savi-mini Single-lumen −1.6171 1.11076 .146
Multi-lumen 4.0559 .85086 < .001
Savi −1.9677 .54620 < .001
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Our current report documents the ability to achieve
dosimetric prescription goals across various applicators
in patients treated with APBI. Low maximum skin dose
and the small high-dose volumes are crucial in maintain-
ing good cosmetic outcomes [2, 26–30]. In HDR inter-
stitial brachytherapy volumes receiving 150 and 200 % of
prescription dose have been shown to correlate with
toxicity [31]. Because of the link between toxicity and
dosimetric parameters, the NSABP B39/RTOG 04-13
requires V150 to be ≤ 70 cm
3 and V200 to be less than
20 cm3 in multi-catheter treatment and V150 to be ≤
50 cm3 and V200 to be less than 10 cm
3 in MammoSite
balloon treatment.
It has been established that multi-lumen applicators
allow for better optimization of dose distribution in
the treatment area, minimizing the risk to nontarget
areas [32, 31, 33]. However, this was not always the
case in our data set as multi-lumen balloon applicators
showed no statistically significant advantage to single-
lumen balloon applicators when comparing DmaxSkinor DmaxRib. However, multi-lumen balloon applicators
were able to achieve smaller high-dose volumes when
compared to single-lumen balloon applicators.
Strut-based intracavitary devices showed a clear advan-
tage in D90, DmaxSkin, and DmaxRib, when compared to
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Fig. 2 Percent of patients within a DmaxSkin range across applicator
subtype (a) DmaxSkin≤ 100 % (b) DmaxSkin 100–125 %




















































































Fig. 3 Percent of patients within a DmaxRib range across applicator
subtype (a) DmaxRib≤ 100 % (b) DmaxRib 100–125 %
(c) DmaxRib≥ 125 %
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seen at the balloon surface [3]. Instead of a balloon,
SAVI devices have a central catheter that is surrounded
by multiple struts containing multiple dwell positions
for the radioactive source. This design allows preferential
treatment to the side of the cavity closest to the surgical
margin and eliminates balloon surface "hot spots" [22].
The unique and flexible design could also account for
the better D90 and D95. Additionally, in balloon-based
applicators, seroma formation has been shown to be a
function of radiation hot spots [34, 23].
Strut-based devices were significantly better at keeping
the DmaxSkin and DmaxRib, under the 125 and 100 %
thresholds. This may result in less skin and rib toxicity.Higher doses to the ribs are associated with fractures
and limiting this value can decrease its incidence [14].
Vargo et. al recently showed telangiectasia development
to be a function of skin dose, where a skin dose >100 %
was the strongest predictor for telangiectasia develop-
ment [23]. Cuttino et al. also showed that the maximal
dose delivered to the skin was significantly associated
with the incidence of telangiectasia and moderate to se-
vere fibrosis, especially when doses were >120 % of the
prescription dose [3]. The higher DmaxSkin in single-
lumen devices was expected as dose constraints are
sometimes not feasible as single-channel balloon cathe-
ters may thin out the anterior tissue plane [35].
Our data was similar to Patel et. al, who showed
strut-based intracavitary implants are associated with
a significantly greater V200 and smaller V150 when
Table 6 The Effect of PTV on D90, D95, DmaxSkin, DmaxRib, V150, and V200
Single-lumen Multi-lumen SAVI SAVI 6-1 mini Total
(n = 34) (n = 64) (n = 243) (n = 253) (n = 594)
r p r p r p r p r p
PTV (cc) vs. D90 .236 .180 .388* .002 .072 .263 .335* < .001 −.082* .046
PTV (cc) vs D95 .102 .565 .382* .002 .129* .044 .405* < .001 .111* .007
PTV (cc) vs DmaxSkin −.153 .388 −.301* .016 −.056 .384 −.350* < .001 −.021 .603
PTV (cc) vs DmaxRib −.217 .217 −.325* .009 −.407* < .001 −.297* < .001 .020 .626
PTV (cc) vs V150 .513* .002 .547* < .001 .808* < .001 .826* < .001 .783* < .001
PTV (cc) vs V200 −.332 .055 −.176 .163 .266* < .001 .586* < .001 −.125* .002
Any relationship is demarcated with *. A strong relationship was defined as an r-value greater than 0.5 or less than −0.5 with p < .05. A weak relationship was
defined as an r-value between 0.25 and 0.5 or −0.25 and −0.5 with p < .05
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cosmetic outcome and skin toxicity has been shown
to be significantly associated with V150 and V200, and
inversely related to the dose homogeneity index
which is defined as (1 – V150/V100). The develop-
ment of fat necrosis has also been shown to be asso-
ciated with V150 and V200, while late subcutaneous
toxicity has only shown associations with dose
homogeneity index [31]. Even though clinical signifi-
cance has not yet been established, the dose homo-
geneity index with SAVI is typically lower than those
seen in interstitial or balloon brachytherapy [22].
V150 and V200 could also have to reach a specific
threshold to result in toxicity. Cuttino et. al saw no
association between outcomes and V150 or V200, but
accounted for this because only 4 % of their patient
population exceeded a V200 of 20 cm
3 [3]. Our results
were similar, as only one patient (0.1 %) exceeded a V200
of 20 cm3.
Because strut-based devices were used on smaller
PTVs we wanted to see how the PTV affected dosimetric
parameters. The only strong correlation in all devices
was seen between PTV and V150 showing that with
greater treatment volumes higher dose volumes should
be expected. PTV and V200 also showed a strong correl-
ation in SAVI-mini devices. PTV was weakly negatively
correlated with max skin dose and max rib dose and
weakly positively correlated with D95 across the strut
based and multi-channel balloon applicators. Because of
this weak correlation it is hard to anticipate maximum
doses to the skin and ribs by PTV alone. While our
study had a minimum skin bridge of 5 mm for all pa-
tients, based on the correlation between smaller PTV
and maximum skin dose the SAVI-mini may prove to be
appropriate for those with less than 5 mm of skin dis-
tance. The variable of skin bridge was eliminated be-
cause we had a cutoff of 5 mm. No patients experienced
a fracture within the follow-up period within the con-
toured rib structures.This study has several limitations. Because this study
was a retrospective analysis there was a lack of
standardization among patients. The group of patients
receiving strut-based devices was also much larger
than the patients receiving single-lumen or multi-lumen
balloon applicators.
Conclusion
The data from this study shows PTV volume is
strongly correlated with V150 in all devices and V200
in strut based devices. Larger PTV volumes result in
greater V150 and V200, which could help predict po-
tential risks for hotspots and resulting toxicities in
these devices. PTV volume is also weakly negatively
correlated with max skin dose and max rib dose,
meaning that as the PTV volumes increase one can
expect slightly smaller max skin and rib doses. Strut
based applicators are significantly more effective in
keeping skin and rib dose constraints under 125 and
100 % when compared to any balloon based applica-
tor and also achieve a significantly better D90.
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